Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04677465Not ApplicableUnknown

Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

Role: lead

NCT03631472Not ApplicableUnknown

Gala Early Feasibility Study of RheOx

Role: lead

NCT04182841Not ApplicableUnknown

RheOx Registry Study in Europe

Role: lead

NCT03385616Not ApplicableCompleted

Gala Treatment for Chronic Bronchitis in Canada

Role: lead

NCT03107494Not ApplicableCompleted

Gala FIH Feasibility Study for the Treatment of Chronic Bronchitis

Role: lead

All 5 trials loaded